secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001193125-24-273467
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO initiates pivotal phase of RGX-202 Duchenne trial with positive functional data; signs $150M ATM facility
--------------------------------------------------------------------------------

- First five patients in Phase I/II showed stable/improved function on NSAA and timed tests, exceeding external natural history controls.
- FDA alignment achieved on accelerated approval pathway; BLA submission expected in 2026.
- Biomarker data: RGX-202 microdystrophin expression highest reported; no serious adverse events.
- New ATM sales agreement with Leerink Partners for up to $150M common stock, replacing prior BofA facility.
- Pivotal trial enrolling ambulatory patients aged 1+, first patient dosed; includes younger boys aged 1-3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524273467/0001193125-24-273467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312524273467/d837203d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-273467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer